[go: up one dir, main page]

MA70850A1 - Composition pharmaceutique d'anticorps anti-cd20 et son utilisation - Google Patents

Composition pharmaceutique d'anticorps anti-cd20 et son utilisation

Info

Publication number
MA70850A1
MA70850A1 MA70850A MA70850A MA70850A1 MA 70850 A1 MA70850 A1 MA 70850A1 MA 70850 A MA70850 A MA 70850A MA 70850 A MA70850 A MA 70850A MA 70850 A1 MA70850 A1 MA 70850A1
Authority
MA
Morocco
Prior art keywords
antibodies
compositions
pharmaceutical composition
disorder
mediated disease
Prior art date
Application number
MA70850A
Other languages
English (en)
Inventor
Ekaterina Aleksandrovna LOMKOVA
Dmitry Valentinovich MOROZOV
Aleksandr Olegovich IAKOVLEV
Aleksandra Aleksandrovna SOZONOVA
Arina Valerevna ZINKINA-ORIKHAN
Daria Dmitrievna BOLSUN
Original Assignee
Joint Stock Company "Biocad"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2022127768A external-priority patent/RU2824627C2/ru
Application filed by Joint Stock Company "Biocad" filed Critical Joint Stock Company "Biocad"
Publication of MA70850A1 publication Critical patent/MA70850A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne le domaine de la pharmacie et de la médecine, en particulier des compositions pharmaceutiques d'anticorps anti-CD20, en particulier le divozilimab, lesdites compositions pouvant être utilisées pour traiter une maladie ou un trouble médié par CD20. L'invention concerne en outre l'utilisation desdites compositions pour le traitement d'une maladie ou d'un trouble médié par CD20, ainsi qu'un procédé de traitement d'une maladie ou d'un trouble médié par CD20, comprenant l'administration desdites compositions.
MA70850A 2022-07-26 2023-07-17 Composition pharmaceutique d'anticorps anti-cd20 et son utilisation MA70850A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2022120466 2022-07-26
RU2022127768A RU2824627C2 (ru) 2022-10-26 Фармацевтическая композиция анти-cd20 антитела и ее применение
PCT/RU2023/050174 WO2024025440A1 (fr) 2022-07-26 2023-07-17 Composition pharmaceutique d'anticorps anti-cd20 et son utilisation

Publications (1)

Publication Number Publication Date
MA70850A1 true MA70850A1 (fr) 2025-10-31

Family

ID=89707083

Family Applications (1)

Application Number Title Priority Date Filing Date
MA70850A MA70850A1 (fr) 2022-07-26 2023-07-17 Composition pharmaceutique d'anticorps anti-cd20 et son utilisation

Country Status (12)

Country Link
CN (1) CN119997972A (fr)
AR (1) AR130008A1 (fr)
CL (1) CL2025000215A1 (fr)
CR (1) CR20250057A (fr)
DO (1) DOP2025000008A (fr)
MA (1) MA70850A1 (fr)
MX (1) MX2025000682A (fr)
PE (1) PE20251691A1 (fr)
TW (1) TW202417044A (fr)
UY (1) UY40364A (fr)
WO (1) WO2024025440A1 (fr)
ZA (1) ZA202500495B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025247408A1 (fr) * 2024-05-31 2025-12-04 百奥泰生物制药股份有限公司 Utilisation d'un anticorps anti-cd20 ou d'un fragment de liaison à l'antigène de celui-ci dans le traitement de maladies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011029892A2 (fr) * 2009-09-11 2011-03-17 F. Hoffmann-La Roche Ag Formulations pharmaceutiques hautement concentrées
RU2724469C2 (ru) * 2018-10-31 2020-06-23 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с cd20

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2572800C1 (ru) * 2014-09-22 2016-01-20 Закрытое Акционерное Общество "Биокад" Новый состав, содержащий конъюгат пэг и интерферон-альфа-2бета, обладающий сниженной болезненностью при введении
BR112018008901A8 (pt) * 2015-11-03 2019-02-26 Janssen Biotech Inc formulações subcutâneas de anticorpos anti-cd 38 e seus usos
JP2023507053A (ja) * 2019-10-12 2023-02-21 バイオ－セラ ソリューションズ リミテッド 抗ｃｄ２０抗体製剤及びｃｄ２０陽性疾患の治療のための抗ｃｄ２０抗体の使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011029892A2 (fr) * 2009-09-11 2011-03-17 F. Hoffmann-La Roche Ag Formulations pharmaceutiques hautement concentrées
RU2724469C2 (ru) * 2018-10-31 2020-06-23 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с cd20

Also Published As

Publication number Publication date
WO2024025440A1 (fr) 2024-02-01
PE20251691A1 (es) 2025-07-02
DOP2025000008A (es) 2025-02-28
UY40364A (es) 2024-02-15
ZA202500495B (en) 2025-08-27
CN119997972A (zh) 2025-05-13
CR20250057A (es) 2025-08-13
TW202417044A (zh) 2024-05-01
MX2025000682A (es) 2025-03-07
AR130008A1 (es) 2024-10-23
CL2025000215A1 (es) 2025-06-13

Similar Documents

Publication Publication Date Title
MA52492B1 (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
MA46430B1 (fr) Thérapie combinée d'agonistes de cnp à libération contrôlée
MA56748B1 (fr) Formes à l'état solide de (s)-2-(((s)-6,8-difluoro-1,2,3,4-tétrahydronaphthalén-2-yl)amino)-n-(1-(2-méthyl-1-(néopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide et utilisations assosiées
MA29444B1 (fr) Antagonistes npy, preparation et utilisations
MA40768B1 (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
MA30325B1 (fr) Composes qui potentialisent le recepteur ampa et leurs utilisations en medecine
MA56038B1 (fr) Inhibiteurs à petite molécule de kinase induisant nf-kb
MA70850A1 (fr) Composition pharmaceutique d'anticorps anti-cd20 et son utilisation
MA63861A1 (fr) Composition pharmaceutique de virus non enveloppé
FR2918571B1 (fr) Compositions antibiotiques a base d'huiles essentielles prophylaxie et traitement d'infections nosocomiales
MA54663A1 (fr) Composition pharmaceutique aqueuse d'un anticorps anti-il17a et son utilisation
MA62992B1 (fr) Formulations de capsules
MA37317A1 (fr) Formulation d'anticorps il-17
Liechti et al. The matrix metalloproteinase inhibitor RS-130830 attenuates brain injury in experimental pneumococcal meningitis
MA53189A1 (fr) Composition pharmaceutique destinée au traitement de l'anémie aplasique
FR3059236B1 (fr) Extraits de plantes du genre tagetes et leurs utilisations
EP3845516A4 (fr) NOUVEL INHIBITEUR DE HIF-1alfa, SON PROCÉDÉ DE PRÉPARATION ET COMPOSITION PHARMACEUTIQUE POUR LA PRÉVENTION OU LE TRAITEMENT D'UNE MALADIE OCULAIRE ASSOCIÉE À L'ANGIOGENÈSE, CONTENANT CELUI-CI EN TANT QUE PRINCIPE ACTIF
MA62939A1 (fr) Composition pharmaceutique de pembrolizumab et son utilisation
EP4331593A4 (fr) Composition pharmaceutique pour la prévention ou le traitement de la maladie de parkinson, et son procédé de préparation
MA58507A1 (fr) Composition pharmaceutique aqueuse de levilimab
MA54940B1 (fr) Dérivés d'acides aminés pour le traitement de maladies inflammatoires
Casale The therapeutic approach to complex regional pain syndrome: light and shade
FR3116216B1 (fr) Procédé de préparation de nanoparticules
FR3145682B1 (fr) Composition pour une utilisation anthelmintique par voie orale à base de fucales, procédé de préparation et utilisation d’une telle composition
Rath et al. A clinical, radiological and IL-6 evaluation of subgingivally delivered simvastatin in the treatment of chronic periodontitis